INTRODUCTION AND OBJECTIVES: Long noncoding RNAs (lncRNAs) have been implicated in many biological processes and mainly function through epigenetic mechanisms. Our previous study, comparing prostate basal and luminal cells via RNA-seq analysis, found that over 20% of the differentially expressed transcripts are lncRNAs.To explore the biological function and molecular mechanism of dysregulated lncRNAs in prostate cancer (PCa) METHODS: The change of maternal expressed gene 3 (MEG3) gene level in PCa patients was analyzed from multiple dimensions and databases. The consequence of MEG3 dysregulation was determined by its influence on cell proliferation, metastasis and interacting with target genes.Tumor suppressive function was measured through in vivo tumor regeneration assay and in vitro cell viability and mobility assays. The interaction of MEG3 and target was tested by RNA immunoprecipitation (RIP) and RNA pulldown assays. Statistical difference and variances were determined by Student t test or Chi-squared test.
INTRODUCTION AND OBJECTIVES: Steroid 5-alpha reductase (SRD5A2) is a critical enzyme for prostatic development and growth. We have found that epigenetic modifications suppress expression of SRD5A2 in one-third of adult prostates, a condition associated with an androgenic to estrogenic switch in adult prostate tissues accounting for changes in hormonal milieu. Our objective is to demonstrate whether the SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in castration-resistant prostate cancer (CRPC).
METHODS: 58 CRPC samples were used for testing: 42 CRPC prostate biopsies were collected from Massachusetts General Hospital (MGH), and 16 baseline and progression bone biopsies from patients treated with abiraterone and dutasteride (NCT01393730). As controls, 23 benign prostatic specimens were collected from patients with benign prostatic hyperplasia. The methylation status of CpG site(s) at SRD5A2 promoter regions was tested. Data was retrieved on primary and secondary ADT treatment response. Overall survival (OS) was calculated from time of diagnosis to time of death. The protein expression of SRD5A2 was determined with immunohistochemistry in 42 CRPC samples (MGH), and then correlated to SRD5A2 methylation status.
RESULTS: Compared with benign prostatic tissue, CRPC samples demonstrated higher SRD5A2 methylation in the whole promoter region (MGH samples: P < 0.0001; samples from NCT01393730: P [ 0.002). Higher ratio of methylation was correlated with better OS (R2 [ 0.11, P [ 0.032). Hypermethylation of specific regions (nucleotides -434 to -4 (CpG#: -39 to CpG#: -2)) was associated with a better OS (11.3AE5.8 vs 6.4AE4.4 years, P [ 0.001) and progression-free survival (PFS, 8.4AE5.4 vs 4.5AE3.9 years, P [ 0.005) with cutoff value of 37.9%. Multivariate analysis showed that SRD5A2 methylation was associated with OS independently (whole promoter region: P [ 0.035; specific region: P [ 0.02). The protein expression of SRD5A2 was negatively correlated with its methylation ratio both in the whole promoter region (R2 [ 0.235, P [ 0.0011) and specific region (CpG#: -39 to CpG#: -2) (R2 [ 0.287, P [ 0.0003).
CONCLUSIONS: Our study show that SRD5A2 hypermethylation in promoter regions, specifically at CpG#: -39 to CpG#: -2, a condition that favors estrogenic as opposed to an androgenic milieu in the prostate, is significantly associated with better survival in CRPC patients treated with ADT. Recognition of epigenetic modifications of SRD5A2, which affects the prostatic hormonal environment, may affect the choices and sequence of available therapies for management of CRPC. METHODS: Patients who were pathologically diagnosed as T2-T4 prostate cancer were included in this study. The tumor and adjacent tissue specimens of prostate cancer patients were collected after operation, and then tissue specimens were embedded in paraffin and were made into tissue sections. Tumor infiltrating T cells (CD4 þ T cells, CD8 þ T cells, Foxp3 þ T cells) and PD1, PD-L1, B7-H4, AR, CK in prostate tissue were performed Immunofluorescent staining using Immunohistochemistry and multiplexed immunofluorescent staining which was based on tyramine signal amplification (TSA) technology. The positioning and quantitation of tumor infiltrating T cells subsets and PD1, PD-L1, B7-H4, AR, CK were analyzed by multi-spectral imaging system. RESULTS: T lymphocytes subsets are mainly located in the interstitial tissue of prostate, while they rarely distribute in the glandular tissue. The distribution of CD4þT cells and CD8þT cells in the interstitial tissue of the adjacent tissue is clearly more than that of the tumor tissue, but the distribution of Foxp3þT cells is not significantly different between the tumor and adjacent tissue. With the development of tumor, the number of CD4þT cells and CD8þT cells in the adjacent tissue gradually decreases, but the number of Foxp3þT cells does not change clearly, and the number of the above cells in the tumor tissue does not change clearly. The expression of PD1 in the adjacent tissue is significantly more than that in the tumor tissue, while the expression of PD-L1 in the tumor tissue is more than that in the adjacent tissue. As the tumor progressesï 1 / 4 OEthe expression of PD1 increases in the adjacent tissue, while PD-L1 increases in the tumor tissue. B7-H4 and AR are both located in the gland tissue of prostate, and the expression of AR in the tumor tissue is more than that in the adjacent tissue and the expression of B7-H4 is not significantly different between the tumor and adjacent tissue, and the expression of B7-H4 and AR shows no clearly changes in different T stages of prostate cancer.
Source of
CONCLUSIONS: The overall characterization of the tumor immune microenvironment of prostate tissue is achieved by multiplexed immunofluorescent staining and multi-spectral imaging technique, revealing that the tumor microenvironment of prostate cancer is in the state of immune suppression. The distribution of tumor infiltrated T cells and the expression of PD1 and PD-L1 are heterogeneous in both space and stage, which indicates that patients with prostate cancer need individualized comprehensive treatments. The tumor immune microenvironment mediated by B7-H4 may have an internal connection with the AR signal pathway, but it still needs to be further explored.
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MP81-18 INVESTIGATING A NOVEL RECOMBINANT ANTIBODY TO ATTENUATE PROSTATE CANCER PROGRESSION BY TARGETING CELL SURFACE GRP78
Ali Al-Hashimi*, Kevin Won, Hamilton, Canada; Elizabeth Pham, Julie Bailis, South San Francisco, CA; Natalie Mariano, South San Francisco, CA; Bobby Shayegan, Richard Austin, Hamilton, Canada INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is characterized by increased activation of the procoagulant protein, tissue factor (TF) that drive tumour progression. We now show that this process is modulated by GRP78 on the cell surface (cs). In PCa GRP78 is a endoplasmic reticulum-resident chaperone that localizes to the cell surface where it functions as a signaling molecule with antigenic properties. In response to csGRP78 presentation, PCa patients produce autoantibodies (AutoAbs) against the N-terminus of GRP78. AutoAbs:csGRP78 complex acts as a potent driver of tumor growth via upregulation of the unfolded protein response (UPR) and TF activity. We hypothesize that inhibiting the binding of anti-GRP78 AutoAbs to csGRP78 will supress UPR and TF activity. Here we describe a recombinant anti-GRP78 antibody (AEP8587) that competes with the binding of AutoAbs to csGRP78 and may act as a novel therapeutic antibody with antitumor activity.
METHODS: Changes in TF activity or UPR markers were evaluated in vitro in the PCa cell line DU145 following treatment with anti-GRP78 AutoAbs or co-treatment with either enoxaparin, a low molecular weight heparin (LMWH), or AEP8587. Protein expression of TF and UPR markers was determined using western blotting and qRT-PCR. TF activity was determined using a real-time continuous assay. AutoAbs were purified PCa patients (St. Joseph's Healthcare Hamilton).
RESULTS: Pre-prostatectomy PCa patients display high levels of anti-GRP78 AutoAbs (w60µg/ml), compared to healthy controls (w5µg/ml). Here, we show that anti-GRP78 AutoAb increases TF activation in vitro and leads to increased tumor progression in a DU145 xenograft model. In contrast, we show a co-treatment of anti-GRP78 AutoAb with either enoxaparin or AEP8587 completely abolishes the AutoAb-mediated increase in TF activity in vitro. Enoxaparin or AEP8587 co-treatment reversed the AutoAb effect on increased UPR markers.
CONCLUSIONS: We have identified anti-GRP78 AutoAb as a driver of PCa progression. Our results indicate that a recombinant antibody, AEP8587, can bind to csGRP78 and prevent the binding of anti-GRP78 AutoAbs. This represents a potential novel means to manage PCa progression.
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